Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00GAM
|
||||
| Former ID |
DIB003145
|
||||
| Drug Name |
Beclanorsen
|
||||
| Synonyms |
SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
|
||||
| Drug Type |
Antisense drug
|
||||
| Indication | Leukemia [ICD9: 208.9; ICD10:C90-C95] | Phase 1/2 | [521795] | ||
| Company |
Santaris Pharma A/S
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C159H201N58O82P15S15
|
||||
| Canonical SMILES |
CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(<br />O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S<br />)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(<br />=S)(O)OC1C2C(OC1(CO2)COP(=S)(O)OC1C2C(OC1(CO2)CO)N1C=C(<br />C(=NC1=O)N)C)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=CC(<br />=NC1=O)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=CN=C2N)N1C=NC2=C1N<br />=CN=C2N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)<br />OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)<br />N1C=CC(=NC1=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=<br />O)N)OP(=S)(O)OCC12COC(C1OP(=S)(O)OCC13COC(C1OP(=S)(O)OC<br />C1C(CC(O1)N1C=NC4=C1N=CN=C4N)O)C(O3)N1C=C(C(=NC1=O)N)C)<br />C(O2)N1C=C(C(=NC1=O)N)C
|
||||
| InChI |
1S/C159H201N58O82P15S15/c1-62-28-208(151(230)191-122(62)165)139-114-118(156(45-218,281-139)46-250-114)296-313(248,328)267-51-159-49-252-116(142(284-159)211-32-66(5)135(221)201-155(211)234)120(159)298-311(246,326)265-44-84-72(21-101(274-84)206-15-10-95(164)190-150(206)229)289-301(236,316)256-35-80-68(17-97(270-80)202-11-6-91(160)186-146(202)225)285-300(235,315)255-34-81-69(18-98(271-81)203-12-7-92(161)187-147(203)226)286-302(237,317)260-39-86-75(24-104(276-86)214-58-182-110-127(170)176-55-179-130(110)214)292-309(244,324)261-40-87-74(23-103(277-87)213-57-181-109-126(169)175-54-178-129(109)213)291-306(241,321)257-36-82-70(19-99(272-82)204-13-8-93(162)188-148(204)227)287-303(238,318)262-41-88-77(26-106(278-88)216-60-184-112-132(216)195-144(172)198-137(112)223)294-308(243,323)259-38-85-73(22-102(275-85)207-31-65(4)134(220)200-154(207)233)290-305(240,320)263-42-89-76(25-105(279-89)215-59-183-111-131(215)194-143(171)197-136(111)222)293-307(242,322)258-37-83-71(20-100(273-83)205-14-9-94(163)189-149(205)228)288-304(239,319)264-43-90-78(27-107(280-90)217-61-185-113-133(217)196-145(173)199-138(113)224)295-312(247,327)266-50-157-47-253-117(141(282-157)210-30-64(3)124(167)193-153(210)232)121(157)299-314(249,329)268-52-158-48-251-115(140(283-158)209-29-63(2)123(166)192-152(209)231)119(158)297-310(245,325)254-33-79-67(219)16-96(269-79)212-56-180-108-125(168)174-53-177-128(108)212/h6-15,28-32,53-61,67-90,96-107,114-121,139-142,218-219H,16-27,33-52H2,1-5H3,(H,235,315)(H,236,316)(H,237,317)(H,238,318)(H,239,319)(H,240,320)(H,241,321)(H,242,322)(H,243,323)(H,244,324)(H,245,325)(H,246,326)(H,247,327)(H,248,328)(H,249,329)(H2,160,186,225)(H2,161,187,226)(H2,162,188,227)(H2,163,189,228)(H2,164,190,229)(H2,165,191,230)(H2,166,192,231)(H2,167,193,232)(H2,168,174,177)(H2,169,175,178)(H2,170,176,179)(H,200,220,233)(H,201,221,234)(H3,171,194,197,222)(H3,172,195,198,223)(H3,173,196,199,224)
|
||||
| InChIKey |
PKMIYXJGDTWFJA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | mRNA of BCL-2 | Target Info | [533110] | ||
| KEGG Pathway | NF-kappa B signaling pathway | ||||
| HIF-1 signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Protein processing in endoplasmic reticulum | |||||
| PI3K-Akt signaling pathway | |||||
| Apoptosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Focal adhesion | |||||
| Neurotrophin signaling pathway | |||||
| Cholinergic synapse | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Toxoplasmosis | |||||
| Tuberculosis | |||||
| Hepatitis B | |||||
| Epstein-Barr virus infection | |||||
| Pathways in cancer | |||||
| MicroRNAs in cancer | |||||
| Colorectal cancer | |||||
| Prostate cancer | |||||
| Small cell lung cancer | |||||
| Pathway Interaction Database | Role of Calcineurin-dependent NFAT signaling in lymphocytes | ||||
| IL2-mediated signaling events | |||||
| IL2 signaling events mediated by PI3K | |||||
| Ceramide signaling pathway | |||||
| Direct p53 effectors | |||||
| RXR and RAR heterodimerization with other nuclear receptor | |||||
| ATF-2 transcription factor network | |||||
| C-MYB transcription factor network | |||||
| HIV-1 Nef: Negative effector of Fas and TNF-alpha | |||||
| Caspase Cascade in Apoptosis | |||||
| Signaling events mediated by Stem cell factor receptor (c-Kit) | |||||
| EPO signaling pathway | |||||
| IL2 signaling events mediated by STAT5 | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-2 Signaling Pathway | |||||
| FAS pathway and Stress induction of HSP regulation | |||||
| Kit receptor signaling pathway | |||||
| IL-3 Signaling Pathway | |||||
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||||
| Apoptosis | |||||
| Nanoparticle triggered autophagic cell death | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Corticotropin-releasing hormone | |||||
| Interleukin-11 Signaling Pathway | |||||
| Prostate Cancer | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in leukocytes - TarBase | |||||
| Integrated Breast Cancer Pathway | |||||
| Integrated Cancer pathway | |||||
| Intrinsic Pathway for Apoptosis | |||||
| Apoptosis Modulation and Signaling | |||||
| TP53 Network | |||||
| Influenza A virus infection | |||||
| IL-5 Signaling Pathway | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.